FDA OKs Sanofi's Teplizumab for Kids
The FDA has approved Sanofi's Teplizumab (Tzield) for children with Stage 3 diabetes, marking a major breakthrough as the first disease-modifying therapy in pediatric care. This innovative drug aims to delay disease progression by targeting the underlying autoimmune destruction of pancreatic beta cells in patients aged 8 to 17.